BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 Q2 P&L / Income Statement

BOSTON SCIENTIFIC CORPORATION (BSX) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales

5,442,000,000 US dollars

Cost of products sold (excluding amortization expense)

1,594,000,000 US dollars

Gross profit

3,848,000,000 US dollars

Operating expenses

2,670,000,000 US dollars

Operating income (loss)

1,178,000,000 US dollars

Other income (expense), net (calculated)

negative 118,000,000 US dollars

Income (loss) before income taxes

1,060,000,000 US dollars

Income tax expense (benefit)

155,000,000 US dollars

Net income (loss)

905,000,000 US dollars

UNITED STATES

3,426,000,000 US dollars

Int'l

2,017,000,000 US dollars

Selling, general and administrative expenses

1,803,000,000 US dollars

Research and development expenses

554,000,000 US dollars

Royalty expense

12,000,000 US dollars

Amortization expense

233,000,000 US dollars

Intangible asset impairment charges

0 US dollars

Contingent consideration net expense (benefit)

negative 16,000,000 US dollars

Restructuring net charges (credits)

8,000,000 US dollars

Litigation-related net charges (credits)

76,000,000 US dollars

Revenue before reconciliation (calculated)

5,443,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Components above reported revenue (calculated)

negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
• Of which attributable to BOSTON SCIENTIFIC CORPORATION: $907.00 M; to noncontrolling interests: −$2.00 M.